

Supporting Information

Antifungal metabolites from *Myxococcus stipitatus* GXUA 01510 for the control of sugarcane Pokkah boeng disease caused by *Fusarium sacchari*

Wang Jiang,^a Qun Hao Li,^a Jiasong Guan,^a Ahmed F. Elkarmout,^{a,b} Zhonghui Ma^{*a} and Zhiwei Su^{*a}

^a National Demonstration Center for Experimental Plant Science Education, College of Agriculture, Guangxi University, Nanning 530004, Guangxi, China.

^b Department of Horticulture, Faculty of Agriculture, Tanta University, Tanta, Egypt.

* Correspondence.

Zhonghui Ma. E-mail: mazhonghui@gxu.edu.cn

Zhiwei Su. E-mail: suzhiwei@gxu.edu.cn

Table of Contents

Table S1. ^1H NMR and ^{13}C NMR data of compounds **1** (in CDCl_3) **3** and phenalamide A_2^1 (in CD_3OD)

Figure S1 Predicted biosynthetic structure of phenalamide

Figure S2 HRESI-MS spectrum of phenalamide D (**1**)

Figure S3 ^1H NMR spectrum of phenalamide D (**1**) in CDCl_3 (500 MHz)

Figure S4 ^{13}C NMR spectrum of phenalamide D (**1**) in CDCl_3 (125 MHz)

Figure S5 HSQC spectrum of phenalamide D (**1**) in CDCl_3

Figure S6 HMBC spectrum of phenalamide D (**1**) in CDCl_3

Figure S7 ^1H - ^1H COSY spectrum of phenalamide D (**1**) in CDCl_3

Figure S8 NOESY spectrum of phenalamide D (**1**) in CDCl_3

Figure S9 IR spectrum of phenalamide D (**1**)

Figure S10 HRESI-MS spectrum of phenalamide E (**2**)

Figure S11 ^1H NMR spectrum of phenalamide E (**2**) in CDCl_3 (500 MHz)

Figure S12 ^{13}C NMR spectrum of phenalamide E (**2**) in CDCl_3 (125 MHz)

Figure S13 HSQC spectrum of phenalamide E (**2**) in CDCl_3

Figure S14 HMBC spectrum of phenalamide E (**2**) in CDCl_3

Figure S15 IR spectrum of phenalamide E (**2**)

Figure S16 HRESI-MS spectrum of phenalamide F (**3**)

Figure S17 ^1H NMR spectrum of phenalamide F (**3**) in CD_3OD (600 MHz)

Figure S18 ^{13}C NMR spectrum of phenalamide F (**3**) in CD_3OD (150 MHz)

Figure S19 HSQC spectrum of phenalamide F (**3**) in CD_3OD

Figure S20 HMBC spectrum of phenalamide F (**3**) in CD_3OD

Figure S21 ^1H - ^1H COSY spectrum of phenalamide F (**3**) in CD_3OD

Figure S22 NOESY spectrum of phenalamide F (**3**) in CD_3OD

Figure S23 IR spectrum of phenalamide F (**3**)

Figure S24 HRESI-MS spectrum of phenalamide G (**4**)

Figure S25 ^1H NMR spectrum of phenalamide G (**4**) in CD_3OD (600 MHz)

Figure S26 ^{13}C NMR spectrum of phenalamide G (**4**) in CD_3OD (150 MHz)

Figure S27 HSQC spectrum of phenalamide G (**4**) in CD_3OD

Figure S28 HMBC spectrum of phenalamide G (**4**) in CD_3OD

Figure S29 ^1H - ^1H COSY spectrum of phenalamide G (**4**) in CD_3OD

Figure S30 NOESY spectrum of phenalamide G (**4**) in CD_3OD

Figure S31 IR spectrum of phenalamide G (**4**)

Figure S32. HPLC purity chromatograms of the isolated new compounds and potent active.

Table S1. ¹H NMR and ¹³C NMR data of compounds **1** (in CDCl₃), **3** and phenalamide A₂¹ (in CD₃OD).

Position	1		3			phenalamide A ₂		
	δ_C	δ_H (J in Hz)	Position	δ_C	δ_H (J in Hz)	Position	δ_C	δ_H (J in Hz)
*	—	—	1	171.8	—	1	171.8	—
*	—	—	2	131.3	—	2	130.6	—
*	—	—	3	135.0	6.93, d (9.4)	3	135.2	6.96, d (9.1)
*	—	—	4	139.4	6.56-6.59, m	4	128.4	6.58, m
*	—	—	5	128.9	6.60, d (14.7)	5	139.9	6.58, m
*	—	—	6	129.0	6.39, d (14.7)	6	127.6	6.40, m
*	—	—	7	133.3	6.41-6.45, m	7	127.7	6.29, m
*	—	—	8	136.5	6.41-6.45, m	8	137.8	6.40, m
1	195.4	9.43, s	9	142.1	5.97, d (14.7)	9	141.0	6.40, m
2	139.7	—	10	83.7	—	10	135.4	—
3	157.1	6.46, dd (9.6, 1.4)	11	85.1	3.66, d (9.4)	11	138.9	5.61, d (9.5)
4	37.2	2.85-2.94, m	12	43.7	2.00-2.04, m	12	37.8	2.82, qdd (6.8, 9.7, 6.6)
5	81.9	3.86, d (8.0)	13	89.4	3.86, d (9.8)	13	82.6	3.84, d (6.6)
6	133.9	—	14	133.6	—	14	136.3	—
7	135.4	5.24, d (9.6)	15	137.0	5.31, d (9.3)	15	134.1	5.27, d (9.4)
8	31.7	2.38-2.47, m	16	33.0	2.43-2.50, m	16	32.8	2.45, m
9	38.9	1.53-1.70, m	17a	40.5	1.54-1.60, m	17a	40.8	1.55, m
			17b		1.65-1.72, m	17b		1.67, m
10	33.9	2.52-2.62, m	18a		2.64-2.69, m	18a	34.9	2.64, m
			18b	34.8	2.54-2.61, m	18b		2.53, m
11	142.5	—	19	143.9	—	19	144.0	—
12	128.4	7.12-7.19, m	20	129.4	7.19, d (7.2)	20	129.4	7.16, d (6.8)
13	128.3	7.23-7.29, m	21	129.3	7.23-7.28, m	21	129.2	7.24, t (7.5)
14	125.7	7.12-7.19, m	22	126.6	7.15, t (7.2)	22	126.5	7.14, t (7.1)
15	128.3	7.23-7.29, m	23	129.3	7.23-7.28, m	23	129.2	7.24, t (7.5)
16	128.4	7.12-7.19, m	24	129.4	7.19, d (7.2)	24	129.4	7.16, d (6.8)
2-Me	9.6	1.79, d (1.4)	2-Me	13.1	1.99, s	2-Me	13.1	2.01, d (1.0)
4-Me	16.6	0.95, d (6.8)	10-Me	22.3	1.29, s	10-Me	12.9	1.84, s
6-Me	11.5	1.60, d (1.4)	12-Me	13.9	0.99, d (6.5)	12-Me	18.3	0.97, d (6.8)
8-Me	21.0	0.98, d (6.8)	14-Me	11.3	1.63, s	14-Me	12.6	1.61, d (1.0)
*	—	—	16-Me	21.4	0.98, d (6.5)	16-Me	21.5	1.00, d (6.6)
*	—	—	1'-Me	17.1	1.19, d (6.8)	1'-Me	17.1	1.22, d (6.7)
*	—	—	1'	49.8	4.04-4.09, m	1'		4.1, qdd (6.7, 5.5, 11.0)
*	—	—	2'	66.1	3.50-3.58, m	2'	66.1	3.56, ddd (5.5, 11.0, 16.5)

1. W. Trowitzsch-Kienast, E. Forche, V. Wray, H. Reichenbach, E. Jurkiewicz, G. Hunsmann and G. Höfle, *Liebigs Ann. Chem.*, 2006, **1992**, 659-664.

*' represents that the space left out corresponds to other similar signals of another compound.

¹H NMR (500 MHz) and ¹³C NMR (125 MHz) for compound 1; ¹H NMR (600 MHz) and ¹³C NMR (150 MHz) for compound 3 and phenalamide A₂.




Figure S1 Predicted biosynthetic structure of phenalamide ².

2. S. Park, H. Hyun, J. S. Lee and K. Cho, *J. Microbiol. Biotechnol.*, 2016, **26**, 1636-1642.




Figure S2 HRESI-MS spectrum of phenalamide D (1).




Figure S3 ^1H NMR spectrum of phenalamide D (1) in CDCl_3 (500 MHz).




Figure S4 ^{13}C NMR spectrum of phenalamide D (1) in CDCl_3 (125 MHz).




Figure S5 HSQC spectrum of phenalamide D (**1**) in CDCl_3 .




Figure S6 HMBC spectrum of phenalamide D (**1**) in CDCl_3 .




Figure S7 ^1H - ^1H COSY spectrum of phenalamide D (**1**) in CDCl_3 .




Figure S8 NOESY spectrum of phenalamide D (**1**) in CDCl_3 .




Figure S9 IR spectrum of phenalamide D (1).




Figure S10 HRESI-MS spectrum of phenalamide E (2).




Figure S11 ^1H NMR spectrum of phenalamide E (**2**) in CDCl_3 (500 MHz).




Figure S12 ^{13}C NMR spectrum of phenalamide E (**2**) in CDCl_3 (125 MHz).




Figure S13 HSQC spectrum of phenalamide E (**2**) in CDCl_3 .




Figure S14 HMBC spectrum of phenalamide E (**2**) in CDCl_3 .




Figure S15 IR spectrum of phenalamide E (2).




Figure S16 HRESI-MS spectrum of phenalamide F (3).




Figure S17 ¹H NMR spectrum of phenalamide F (**3**) in CD₃OD (600 MHz).




Figure S18 ¹³C NMR spectrum of phenalamide F (**3**) in CD₃OD (150 MHz).




Figure S19 HSQC spectrum of phenalamide F (**3**) in CD₃OD.




Figure S20 HMBC spectrum of phenalamide F (**3**) in CD₃OD.




Figure S21 ^1H - ^1H COSY spectrum of phenalamide F (**3**) in CD_3OD .




Figure S22 NOESY spectrum of phenalamide F (**3**) in CD_3OD .




Figure S23 IR spectrum of phenalamide F (3).




Figure S24 HRESI-MS spectrum of phenalamide G (4).




Figure S25 ^1H NMR spectrum of phenalamide G (**4**) in CD_3OD (600 MHz).




Figure S26 ^{13}C NMR spectrum of phenalamide G (**4**) in CD_3OD (150 MHz).




Figure S27 HSQC spectrum of phenalamide G (**4**) in CD₃OD.




Figure S28 HMBC spectrum of phenalamide G (**4**) in CD₃OD.




Figure S29 ^1H - ^1H COSY spectrum of phenalamide G (4) in CD_3OD .




Figure S30 NOESY spectrum of phenalamide G (4) in CD_3OD .




Figure S31 IR spectrum of phenalamide G (4).




Figure S32. HPLC purity chromatograms of the isolated new compounds and potent active.